Skip to main content
All lobbying filings

REGENERON PHARMACEUTICALS, INC

Lobbying for REGENERON PHARMACEUTICALS, INC

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · New York · House · Senate · $640,000.00 expenses · posted Apr 20, 2026

Official filing document

 Lobbying activity 5
Health Issues

Privacy legislation related to biopharmaceutical manufacturers; Food and Drug Administration issues related to biopharmaceutical manufacturers; National security issues related to biopharmaceutical manufacturers; Public-private contracts for innovation in the biopharmaceutical space; Issues related to defense spending; Issues related to step therapy; Issues related to health extenders; Issues related to Pandemic Preparedness and Response Program.

Medicare/Medicaid

Medicare, Medicaid, and other drug pricing issues relating to biopharmaceutical manufacturers.

Copyright/Patent/Trademark

Patent issues relating to biopharmaceutical manufacturers; Intellectual property legislation related to biopharmaceutical manufacturers; Issues relating to WTO TRIPS waivers.

Trade (domestic/foreign)

Trade and tariff issues related to corporations.

Taxation/Internal Revenue Code

Tax and inflation issues related to corporations.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem